How has been the historical performance of Concord Biotech?

Answer:The historical performance of Concord Biotech shows a consistent growth trend in net sales and profitability over the past four years.

Breakdown:
Concord Biotech's net sales increased from 712.93 Cr in Mar'22 to 1,200.09 Cr in Mar'25, reflecting a strong upward trajectory. Total operating income followed a similar pattern, rising from 712.93 Cr to 1,200.09 Cr during the same period. The company's total expenditure, excluding depreciation, also grew, from 439.66 Cr in Mar'22 to 693.76 Cr in Mar'25. Operating profit (PBDIT) saw significant growth, climbing from 296.69 Cr in Mar'22 to 550.78 Cr in Mar'25, while profit before tax increased from 241.16 Cr to 495.87 Cr. The profit after tax also rose from 178.57 Cr in Mar'22 to 372.96 Cr in Mar'25, indicating improved profitability margins, with the PAT margin reaching 30.97% in Mar'25. On the balance sheet, total assets grew from 1,312.79 Cr in Mar'22 to 2,034.25 Cr in Mar'25, while total liabilities increased from 1,312.79 Cr to 2,034.25 Cr. Cash flow from operating activities showed a slight decline from 265.00 Cr in Mar'24 to 244.00 Cr in Mar'25, and the company experienced a net cash outflow of 14.00 Cr in Mar'25, contrasting with a net inflow of 11.00 Cr in Mar'24. Overall, Concord Biotech's financial metrics indicate a robust growth trajectory in sales and profitability, despite fluctuations in cash flow.